Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

Exclusion Criteria

• •Presence of other active skin diseases at or near the Target Lesion area to be treated
• •A subject whose disease is so widespread or severe that, in the opinion of the investigator, oral antibiotic treatment is needed
• •Signs and symptoms of another current infection requiring antibiotic treatment
• •Tympanic temperature at Screening/Baseline exceeding 38 degrees Celsius (100.4 degrees Fahrenheit) in a pediatric subject or 37.8 degrees Celsius (100 degrees Fahrenheit) in an adult subject
• •History of Hepatitis B or C, HIV/ AIDS, or other immunodeficiency disease
• •Concurrent or recent scabies infection or lice infestation (pediculosis) of the scalp
• •Use of systemic antibiotics or systemic steroids within 14 days prior to study entry. A history of three or more courses of systemic antibiotics within the 3 month period immediately prior to screening will also be considered exclusionary
• •Use of topical antibiotics, topical antibacterials, topical antifungals or topical steroids within 14 days prior to study entry on any skin lesion (as deemed significant by the Investigator by virtue of the lesion's nature and/or position to impact on the effectiveness of the study drug)
• •Participation in any other clinical study or use of any investigational drugs or investigational device within 30 days prior to enrollment
• •Presence of secondarily infected traumatic lesions (e.g. surgical wounds, animal/insect bites, burns, lacerations and abrasions).
• •Another family member in same household currently enrolled in this study or another family member in the same household with active impetigo